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The evaluation of the impact of probiotics on host health could help to understand how they can be used in the prevention of
diseases. On the basis of our previous studies and in vitro assays on PBMC and Caco-2 ccl20:luc reporter system presented in
this work, the strain Lactobacillus kefiri CIDCA 8348 was selected and administrated to healthy Swiss mice daily for 21 days. The
probiotic treatment increased IgA in feces and reduced expression of proinflammatory mediators in Peyer Patches and mesenteric
lymph nodes, where it also increased IL-10. In ileum IL-10, CXCL-1 andmucin 6 genes were upregulated; meanwhile in colonmucin
4 was induced whereas IFN-𝛾, GM-CSF, and IL-1𝛽 genes were downregulated. Moreover, ileum and colon explants showed the
anti-inflammatory effect of L. kefiri since the LPS-induced increment of IL-6 and GM-CSF levels in control mice was significantly
attenuated in L. kefiri treated mice. Regarding fecal microbiota, DGGE profiles allowed differentiation of experimental groups in
two separated clusters. Quantitative PCR analysis of different bacterial groups revealed only significant changes in Lactobacillus
population. In conclusion, L. kefiri is a good candidate to be used in gut inflammatory disorders.
1. Introduction
Interactions between commensal bacteria, intestinal epithe-
lial and immune cells play a crucial role in the main-
tenance of gut homeostasis [1, 2]. Microbial recognition
through pattern-recognition receptors induces the expres-
sion and release of many different immune mediators, such
as chemokines and pro- or anti-inflammatory cytokines
which contribute to orchestrating both the innate and the
adaptive immune response [3, 4]. The use of probiotics
to modulate immune responses at mucosal and systemic
level constitutes a very interesting alternative regarding the
prevention and treatment of infectious diseases [5, 6] and
different immunopathologies such as inflammatory bowel
diseases and allergies [7–9] or metabolic disorders [10, 11].
Kefir grains are constituted by a complex symbiotic
microbiota, and they are used to obtain fermented milks
named “kefir” [12]. Several health-promoting properties
such as immunological, antimicrobial, antitumoral, and
hypocholesterolemic effects have been associated with kefir-
consumption [13–17] and the study of the beneficial proper-
ties attributed to kefir-isolated microorganisms constitutes a
field of great interest for the development of functional foods.
Immunomodulatory properties have been reported for
different yeasts and bacteria isolated from kefir grains.
Among kefir yeasts, Kluyveromyces marxianus CIDCA 8154
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and Saccharomyces cerevisiae CIDCA 8112 downregulate
intestinal epithelial innate response through a mechanism
dependent on NF-kB modulation [18]. In the case of lactic
acid bacteria retrieved from kefir, L. kefiranofaciens has been
proven to ameliorate colitis in a DSS-induced murine model
[19] and to produce antiasthmatic effects on ovalbumin-
allergic asthma mice [20]. On the other hand, Carey and
Kostrzynska [21] showed that L. kefiri attenuates the proin-
flammatory response in intestinal epithelial cells induced by
Salmonella Typhimurium and Hong et al. [22] showed its
influence onTh1 and proinflammatory cytokines production
on macrophages.
One of the most important lactobacilli retrieved from
kefir is Lactobacillus kefiri [23–26]. In previous studies, our
workgroup has demonstrated that secretion products and
surface proteins from L. kefiri exert a protective action
against the invasion of Salmonella enterica serovar Enteritidis
to Caco-2 cells [27] and also against the cytotoxic effects
of clostridial toxins on Vero cells [28]. Moreover, L. kefiri
strains have been proven to be safe [29] and to adhere to
gastrointestinal mucus [30]. On the other hand, L. kefiri
strains preserve a high percentage of viability after both
spray-drying [31, 32] and freeze-drying procedures [33]. All
the mentioned properties show the potentiality of L. kefiri as
probiotic microorganism.
The study of the mechanisms underlying probiotic effect
on the host on nonpathological conditions may be helpful
for evaluating safety and further application of beneficial
microorganisms in the prevention and treatment of different
diseases. Taking into account the potentiality of L. kefiri as a
novel probiotic, we propose to evaluate the immunomodu-
latory properties of kefir-isolated L. kefiri strains by in vitro
and in vivo assays, along with changes in gut microbiota
composition induced by L. kefiri administration.
2. Materials and Methods
2.1. Bacterial Strains and Growth Conditions. Lactobacillus
kefiri CIDCA 83111, 83113, 83115, 8321, 8325, 8345, and 8348
were isolated from kefir grains [12]. L. kefiri JCM 5818 was
obtained from the Japanese Collection of Microorganisms
(Reiken, Japan). Previously, L. kefiri CIDCA 83115, 8321,
8345, and 8348 were characterized as aggregating strains;
meanwhile L. kefiri CIDCA 83111, 83113, and JCM 5818 were
described as nonaggregative strains [34]. Lactobacilli were
cultured in MRS-broth (DIFCO, Detroit, USA) 37∘C for 48 h
in aerobic conditions. Frozen stock cultures were stored at
−80∘C in skim milk until use.
2.2. Stimulation Assay with Caco-2 ccl20:luc Reporter System.
The experiments were performed as described previously
[35]. Briefly, Caco-2 cells stably transfected with a luciferase
reporter construction under the control of CCL20 promoter
(Caco-2 ccl20:luc) [36] were cocultured 2 hwith a suspension
of the L. kefiri strains (107 CFU per well) to be tested
(multiplicity of incubation = 100).Then, cells were stimulated
using flagellin from Salmonella enterica ser. Typhimurium
(FliC) (1 𝜇gmL−1) for 6 h. Luciferase activity was measured
in a Labsystems Luminoskan TL Plus luminometer (Thermo
Scientific, USA) using a luciferase assay system (Promega,
Madison, WI, USA). Luminescence was normalized and
expressed as the percentage of themean of stimulated control
(NAL).
2.3. PBMC Stimulation Experiments. Peripheral blood sam-
ples pretested for the absence of HIV or hepatitis virus infec-
tions were obtained from healthy volunteers (EFS Aquitaine,
Bordeaux Blood Bank). Human PBMCs were isolated by
centrifugation on Ficoll-Hypaque gradients. After washing, 2
× 106 cells/well were cultured in 12-well plates in RPMI-1640
medium supplemented with 2 g L−1 NaHCO
3
, 300mg L−1 L-
glutamine, 100 𝜇gmL−1 streptomycin, 100 IUmL−1 penicillin
(Sigma Chemical Co., St. Louis, MO, USA) and 10% FBS.
L. kefiri stimulation experiments on PBMC were per-
formed coculturing 2 × 107 bacteria per well (MOI = 10)
during 24 h at 37∘C in an atmosphere of 95% air and 5% CO
2
.
Culture supernatants were collected and kept at −80∘C until
cytokines analysis. Experiences were realized in triplicate.
Cell viability was not affected after 24 h of coincubation with
bacteria (data not shown).
2.4. Quantification of Cytokine Levels in Culture Supernatants.
Profiles of cytokines were analyzed after L. kefiri strain
stimulation of PBMC using the Human Th1/Th2 11plex
FlowCytomix Kit (eBioscience). It was designed to measure
human IFN-𝛾, IL-1𝛽, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-
12 p70, TNF-𝛼, and TNF-𝛽. Analysis was performed in a
flow cytometer BD Accuri C6 (BD Biosciences). TGF-𝛽 was
measured using the eBioscience human/mouse TGF beta 1
Ready-SET-Go! ELISA Kit (minimum detectable concentra-
tion 8.0 pg/mL).
2.5. Mice. Male Swiss albino mice, 4-week-old (Janvier, Le
Genest St Isle, France), were quarantined 2 weeks after arrival
and were housed under standard laboratory conditions with
free access to food and water. The temperature was kept at
22∘C and a 12-hour light/dark schedule was maintained. All
procedures were performed according to the guidelines of
the local ethics committee and in strict accordance with the
guidelines issued by the European Economic Community
“86/609.” Mice were randomly divided into two groups (𝑛 =
12/group) and received by gavage 108 CFU of L. kefiriCIDCA
8348 (Lk group) or PBS (control group) daily for 7 days and 21
days; at each time point 6 mice of each group were sacrificed.
2.6. Tissue and Stool Sampling. Stools were collected at days 7,
14, and 21 and stored at −80∘C until analysis. At the end of the
experimental protocol, day 7 or 21, ileum and colon samples
were collected and were preserved at −20∘C in RNAlater
(QIAGEN, Hilden, Germany) until RNA extraction. On day
21 Peyer Patches (PP) and mesenteric lymph nodes (mLN)
were also removed and preserved at −20∘C in RNAlater
for expression analysis, and ileum and colon explants were
collected in RPMI medium and processed immediately in
order to analyze cytokines’ secretion.
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2.7. Quantification of Gene Expression in
Tissue Samples by qRT-PCR
2.7.1. RNA Extraction. Total RNA was isolated using the
RNeasy Mini Kit (QIAGEN, Hilden, Germany) with an
additional DNase treatment (TurboDNA-free, Ambion, Inc.)
according to the manufacturer’s instructions.
2.7.2. cDNA Synthesis. One 𝜇g of total RNA was reverse-
transcribed using the Maxima Reverse Transcriptase (Fer-
mentas, France) with anchored-oligo (dT) 18 primer, accord-
ing to manufacturers’ instructions.
2.7.3. Quantitative PCR. Quantitative real-time PCR analyses
were performed using a CHROMO 4 System (Bio-Rad).
The reaction mixture comprised Maxima SYBR Green/ROX
qPCR Master Mix (Fermentas, France), 0.5 𝜇mol L−1 of each
primer, and the respective standardized cDNA as a tem-
plate. Target gene copy numbers were normalized against
the housekeeping genes hypoxanthine phosphoribosyltrans-
ferase (HPRT) and 𝛽2 microglobulin (B2m). Cytokine and
chemokine genes evaluated were il1b, il6, il10, il12p70, il17a,
il23, ifng, tnfa, tgfb, cxcl1, baff, april, gmcsf ; the transcription
factors studiedwere foxp3 and rorgt; epithelial barrier and IgA
related genes were zo-1, occludin, and pIgR; mucin genes were
muc1,muc2,muc3,muc4,muc6, andmuc13. Primer sequences
and PCR conditions are available upon request (E-mail:
maria.urdaci@agro-bordeaux.fr). A negative control reaction
without template was included for each primer combination.
2.8. Evaluation of Cytokine Secretion by Ileum and Colon
Explants. Ileum and colon explants were cultured in RPMI
medium supplemented with 10% fetal bovine serum (Gibco-
Invitrogen, Carlsbad, CA, USA), 100𝜇gmL−1 streptomycin
and 100 IUmL−1 penicillin G, 100 𝜇gmL−1 gentamycin or
RPMI complete medium with addition of 10 𝜇gmL−1 of LPS
from E. coli as a stimulus (all from Sigma Chemical Co., St.
Louis,MO, USA) for 24 h at 37∘C in an atmosphere of 95% air
and 5% CO
2
[37]. Supernatants were collected, centrifuged,
and frozen for later cytokines (IL-6, IL-4, IL-10, IL-17A, IFN-
𝛾, and GM-CSF) measurements (Ready-SET-Go! ELISA Kit,
eBioscience, France). All assays were performed according
to the manufacturer’s instructions. The minimum detectable
concentrations were 4.0 pgmL−1 (IL-6, IL-4, and GM-CFS),
15 pgmL−1 (IFN-𝛾), and 30.0 pgmL (IL-10 and IL-17A).
2.9. Determination of Total IgA in Stools. At 7, 14, and 21 days
after L. kefiri treatment the level of total IgA in stools was
measured by ELISA according to the technique described by
BD Pharmigen. Briefly, Maxisorp Nunc plates were coated
overnight with purified rat anti-mouse IgA (BD 556969).The
plates were washed with PBS containing 0.05% v/v Tween
20 (PBS-T) and blocked with FBS 10% v/v in PBS. Plates
were incubated for 2 h at room temperature with purified
mouse IgA kappa (BD 553476) or fecal samples. Plates were
revealed using biotin rat anti-mouse IgA (BD 556978), strep-
tavidin horseradish peroxidase (BD 554066), and trimethyl-
benzidine (TMB substrate reagent set BD OptEIA 555214).
Using a Mutliscan FC microplate reader (Thermo Scientific)
absorbance was read at 450 nm. All determinations were
performed in triplicate.
2.10. Microbiota Population Analysis in Feces by q-PCR.
Microbiota population analysis in feces was performed on
the day 21 of the experience. DNA extraction was per-
formedusing theNucleoSpin Soil GenomicDNA isolation kit
(Macherey-Nagel) according to the manufacturer’s instruc-
tions except the feces solubilisation step. Quantification of
bacterial populations was carried out using primers synthe-
sized by Biomers (France). PCR reactions were performed
on a CHROMO 4 System (Bio-Rad) using Maxima SYBR
Green/ROX qPCR Master Mix (Fermentas, France). Twenty
ng DNA and 0.2 𝜇mol L−1 of each primer were used in
PCR mix. A negative control reaction without template was
included for each primer combination. Melting curve was
conducted from 70∘C to 90∘C read every 0.5∘C during 2 s.
The resulting data were collected and analyzed using Opticon
Monitor. Standard curves were made with pure cultures of
appropriate strains extracted using the same protocol as feces.
Primers sequences are able on Table 1.
2.11. Qualitative Analysis of Fecal Microbiota by PCR-DGGE.
HDA1 and HDA2-GC (GC clamp required for DGGE
analysis [38], targeting the V2-V3 region [39]) were used
to assess microbial diversity in each sample. The PCR
products were separated in 8% polyacrylamide gels (37.5 : 1
acrylamide : bisacrylamide) with a range of 30–50% dena-
turing gradient (100% denaturant consisted of 7M urea and
40% deionized formamide) cast with Bio-Rad’s Model 475
gradient delivery system (BioRad, Hercules, CA, USA). The
electrophoresis was performed in TAE 0.5X buffer for 5 h at a
constant electric current of 125mA and a temperature of 60∘C
with the DCode Mutation Detection System (Bio-Rad, Her-
cules, CA, USA). Clustering analysis was performed using
theUPGMA (unweighted pair groupmethodwith arithmetic
mean clustering algorithm) to calculate the dendrograms.
2.12. Statistical Analysis. Statistical comparisons for signifi-
cant differences were performed according to Student’s 𝑡-test.
Differences with 𝑃 < 0.05 were considered significant.
3. Results
3.1. Cytokines Profile of PBMC Cocultured with L. kefiri
Strains. A preliminary screening of the eight L. kefiri strains
was carried out using PMBC. PBMC and bacteria coculture
assays were performed and profiles of cytokines secreted
during incubation with the strains were analyzed. The levels
of IL-2, IL-4, IL-5, TNF-𝛽 y TGF-𝛽1 were under the lower
range of reliable detection. Meanwhile a significant increase
in IL-1𝛽, IL-6, IL-10, TNF-𝛼, IL-8, and IL-12 p70 concentra-
tions was observed for all tested microorganisms (Table 2).
In an attempt to predict the type of Th response they could
promote, we analyzed the TNF-𝛼/IL-10 and IL-10/IL-12 ratios
(Table 3).
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Table 1: Sequences of oligonucleotide primers.
Population Forward and reverse primers (5󸀠-3󸀠) Reference
Total bacteria (HDA) ACTCCTACGGGAGGCAGCAGGTATTACCGCGGCTGCTGGCAC
[39]
Lactobacillus group AGCAGTAGGGAATCTTCCAATTYCACCGCTACACATG
Firmicutes GGAGYATGTGGTTTAATTCGAAGCAAGCTGACGACAACCATGCAC
[66]
Bacteroidetes GGARCATGTGGTTTAATTCGATGATAGCTGACGACAACCATGCAG
Faecalibacterium prausnitzii AGATGGCCTCGCGTCCGACCGAAGACCTTCTTCCTCC [67]
Escherichia coli CATGCCGCGTGTATGAAGAACGGGTAACGTCAATGAGCAAA [68]
Prevotella group CACCAAGGCGACGATCAGGATAACGCCYGGACCT [69]
Clostridium leptum group GCACAAGCAGTGGAGTCTTCCTCCGTTTTGTCAA [70]
Enterococcus spp. CCCTTATTGTTAGTTGCCATCATTACTCGTTGTACTTCCCATTGT
Clostridium coccoides group CGGTACCTGACTAAGAAGCCTTCCTCCGTTTTGTCAA [71]
Bifidobacterium spp. TCGCGTCYGGTGTGAAAGCCACATCCAGCRTCCAC
Bacteroides fragilis group CTGAACCAGCCAAGTAGCGCCGCAAACTTTCACAACTGACTTA [72]
Segmented filamentous bacteria GACGCTGAGGCATGAGAGCATGACGGCACGGATTGTTATTCA [73]
Lactobacillus murinus GTGGCGAACGGGTGAGTAAGCACCTGTTTCCAAGTGTTATCC [74]
Akkermansia muciniphila CAGCACGTGAAGGTGGGGACCCTTGCGGTTGGCTTCAGAT [75]
Table 2: Cytokine production after exposing PMBCs for 24 h to L. kefiri strains. Cytokines concentrations in culture cell supernatant
(pgmL−1) were measured using Flow Human Th1/Th2 11plex FlowCytomix Kit (eBioscience). The results are expressed as mean ± SD of
experiments performed with three different donors.
L. kefiri IL-1𝛽 IL-6 IL-8 IL-10 IFN-𝛾 TNF-𝛼 IL-12p70
CIDCA 8321 1294 ± 526 1552 ± 709 5771 ± 1284 205 ± 76 131 ± 22 10436 ± 3785 312 ± 72
CIDCA 8325 2050 ± 75 2571 ± 94 4824 ± 531 313 ± 11 59 ± 38 16169 ± 45 572 ± 94
CIDCA 8345 1655 ± 8 2033 ± 15 4399 ± 106 230 ± 3 85 ± 20 15368 ± 1075 449 ± 21
CIDCA 8348 1936 ± 10 2719 ± 13 3855 ± 40 435 ± 90 83 ± 4 13551 ± 198 502 ± 121
CIDCA 83115 1023 ± 60 1778 ± 12 3621 ± 34 192 ± 9 49 ± 2 8613 ± 500 738 ± 206
CIDCA 83111 604 ± 83 2401 ± 81 3806 ± 167 253 ± 1 103 ± 23 9908 ± 175 815 ± 189
CIDCA 83113 1148 ± 26 1722 ± 95 3920 ± 202 201 ± 11 53 ± 22 7514 ± 427 475 ± 59
JCM 5818 591 ± 103 919 ± 40 4228 ± 12 84 ± 2 62 ± 13 6872 ± 1647 246 ± 94
Nonstimulated PBMC 35 ± 2 71 ± 6 418 ± 202 21 ± 1 15 ± 11 175 ± 5 41 ± 13
The highest TNF-𝛼/IL-10 ratio was observed for the
nonaggregating strain L. kefiri JCM 5818 and the lowest
for the autoaggregative strain L. kefiri CIDCA 8348. In
agreement with these results, L. kefiri CIDCA 8348 showed
the highest IL-10/IL-12 ratio while L. kefiri JCM 5818 was,
among other strains such as CIDCA 83111, 83113, and 83115,
in the opposite ratio, expecting a poor anti-inflammatory
effect.
3.2. Regulation of Caco-2 ccl20:luc Reporter System by L. kefiri
Strains. The ability of the eight strains of L. kefiri tomodulate
intestinal innate response to proinflammatory stimuli such as
flagellin (FliC) was studied using a Caco-2 ccl20:luc reporter
system [18, 36]. Only three strains (CIDCA 8348, 83111,
and JCM 5818) downregulated cell activation induced by
FliC (Figure 1), suggesting their potential anti-inflammatory
properties.
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Table 3: TNF-𝛼/IL-10 and IL-10/IL-12 ratio determined after in vitro
PBMC stimulation with L. kefiri strains. Means with the same letter
for each parameter are not significantly different.
L. kefiri TNF-𝛼/IL-10 IL-10/IL-12
CIDCA 8321 50.9 ± 11.4c,d 0.66 ± 0.24d,e,f
CIDCA 8325 51.7 ± 0.1d 0.55 ± 0.06e
CIDCA 8345 66.8 ± 4.7e 0.51 ± 0.02e
CIDCA 8348 31.2 ± 0.5b 0.87 ± 0.18f
CIDCA 83115 44.9 ± 2.6c 0.26 ± 0.01b
CIDCA 83111 39.2 ± 0.7c 0.31 ± 0.02c
CIDCA 83113 37.4 ± 2.1c 0.42 ± 0.02d
JCM 5818 81.8 ± 19.6f 0.34 ± 0.03c
Nonstimulated PBMC 8.3 ± 0.2a 0.005 ± 0.002a
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Figure 1: Modulation of proinflammatory response in Caco-2
ccl20:luc reporter system by L. kefiri strains. NAL: normalized
average luminescence expressed as percentage of activity induced
with flagellin stimulation; FliC: Salmonella-isolated flagellin; Basal:
without any stimulation. Results are expressed as mean ± standard
deviation and are representative of at least three independent
experiments. ∗𝑃 < 0.01.
L. kefiri CIDCA 8348 was chosen to perform in vivo
studies on Swiss mice since parameters associated with safety
and other beneficial properties have been previously demon-
strated [29].Moreover, L. kefiriCIDCA8348 is an aggregative
strain.This is an important property for probiotics since it has
been proposed that aggregation represents a mechanism by
which gastrointestinal commensals adhere to each other and
it could allow them to colonize persistently in biofilms on the
host’s mucosa [40].
3.3. Kinetics of Fecal IgA Response after Oral Administration of
L. kefiri CIDCA 8348 in Swiss Mice. Stool suspensions were
assayed for total IgA by ELISA to evaluate the induction of
mucosal IgA (Figure 2). An induction was observed after 14
days of probiotic administration and the levels continue ris-
ing after 21 days. Even though no differences in IgA secretion
were observed after 7 days of treatment between groups, flow
cytometry quantified IgA+ cells were significantly higher in
mLN from Lk group (data not shown).
3.4. Effect of L. kefiri Administration onGene Expression of Gut
Mucosa. The expression of cytokines, chemokines, mucins,
and epithelial barrier genes as well as IgA related genes was
∗
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Figure 2: IgA quantification from fecal samples taken on day 7, 14,
or 21 from control mice and L. kefiri treated mice (Lk). Results are
expressed as mean ± standard deviation. ∗𝑃 < 0.05.
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Figure 3: Gene expression ratio in ileum (black) and colon (white)
of Lk group versus control group after 7 days of L. kefiri administra-
tion.The x-axis of the plot represents log
2
relative expression level of
the gene and the y-axis displays the−log
10
P (statistical significance).
The names of the genes which displayed significant differences are
included.
studied by qRT-PCR in ileum and colon after 7 and 21 days of
oral administration of L. kefiri CIDCA 8348.
As shown in Figure 3, a seven-day treatment significantly
downregulated IL-1𝛽 and IL-17A gene expression in ileum;
meanwhile mucin 3 and mucin 6 were upregulated. In
contrast, in colon only gene expression of mucin 4 was
modified.
The administration of L. kefiri for a longer period, 21
days, produced higher expression levels of IL-10, CXCL-1,
and mucin 6 genes in ileum (Figure 4(a)). In colon, down-
regulation of IFN-𝛾, GM-CSF, and IL-1𝛽 genes was observed
together with the upregulation of mucin 4 (Figure 4(a)).
The effect of L. kefiri treatment for 21 days on gene
expression was also evaluated in Peyer patches (PP) and
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Figure 4: Gene expression ratio of Lk group versus control group after 21 days of L. kefiri administration. The x-axis of the plot represents
log
2
relative expression level of the gene and the x-axis displays the −log
10
P (statistical significance).The names of the genes which displayed
significant differences are included. (a) Expression in ileum (black) and colon (white). (b) Expression in PP (black) and mLN (white).
mesenteric lymph nodes (mLN) (Figure 4(b)). In PP the
expression of IL-23, IFN-𝛾, and IL-6 was downregulated.
Interestingly, in mLN not only proinflammatory mediators
(IL-6, IL-23, IL-17A, and GM-CSF) and ROR𝛾t transcription
factor were downregulated but also IL-10 gene expressionwas
increased.
3.5. Ex Vivo Mice Intestinal Explants to Study Mucosal Anti-
Inflammatory Effect of L. kefiri. To analyze the ability of L.
kefiri treatment to modulate the mucosal immune response
in a proinflammatory environment, ex vivo experiments were
performed stimulating ileum and colon explants with LPS
from not treated (control) and 21-day L. kefiri treated mice.
LPS stimulation induced an increment of IL-6 and GM-
CSF levels in control mice (Figures 5(a) and 5(b)). These
increments were significantly attenuated in both ileum and
colon explants of L. kefiri treated mice (Figures 5(a) and
5(b)). Moreover, in colon explants from Lk group a higher
secretion of IL-10 was observed in LPS stimulated samples
(Figure 5(b)). The levels of IL-4, IL-17, IFN-𝛾, and TNF-𝛼
were undetectable in both Lk and control mice explants.
3.6. Effect of L. kefiri Administration on Fecal Microbiota.
The qualitative profile of fecal microbiota was determined by
PCR-DGGE (Figure 6(a)). Microbial diversity was assessed
by the number of amplification bands generated from each
sample. There were no differences between control and
Lk group (32 ± 3 and 30 ± 2, resp.). However, changes
in the microbial community composition were produced
since the cluster analysis based on the Pearson product-
moment correlation coefficient and UPGMA linkage allowed
differentiation of the experimental groups in two clusters
(Figure 6(b)).
As expected, an increment in Lactobacillus population
was observed by qPCR but quantitative differences were not
observed in the twomajor phyla, Firmicutes or Bacteroidetes
(Figure 6(c)). Moreover, no significant changes were detected
in other evaluated bacterial populations (Table 1).
4. Discussion
In the last years, an increasing number of in vitro and in
vivo experiments have supported the idea that probiotic
microorganisms confer their health benefits to the host by
interacting with the immune system, particularly through
establishing and maintaining a balance between pro- and
anti-inflammatory cytokines [41, 42]. In kefir, bacteria and
yeasts exist in symbiotic association and contributed to
beneficial properties. Several authors have demonstrated the
ability of kefir to modulate the mucosal immune response
in mice and suggest that a Th1 response was controlled by
Th2 cytokines [15, 16]. Some immunological effects were
attributed to the formation of bioactive peptides during milk
fermentation and also to production of exopolysaccharides as
kefiran [13]. However, features regarding the effects of bacte-
ria remain very important. It has been recently described that
one strain of L. kefiranofaciens protects mice in a model of
allergy [20] and also in an experimental model of colitis [19],
but to our knowledge, our work constitutes the first report of
the in vivo immunomodulatory activity of L. kefiri.
In the present work we demonstrated that L. kefiri strains
induced the secretion of proinflammatoryTh1mediators such
as IL-1𝛽, IFN-𝛾, IL-6, IL-12p70, and TNF-𝛼 in PBMC as well
as the production of the Th2 cytokine IL-10. These findings
are not surprising, since several authors have reported the
upregulation of these proinflammatory cytokines by probi-
otic bacteria on PBMC [6, 43–45] or in mice macrophages
by L. kefiranofaciens [22]. However, we found that L. kefiri
strains stimulate immune cells to produce different ratios of
cytokines, suggesting that they could possess different T cell
polarizing abilities.
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Figure 5: Cytokine’s release in supernatants of (a) ileum and (b)
colonic explants cultured for 24 h in the presence of LPS. Results are
expressed as mean ± standard deviation. ∗𝑃 < 0.05.
Cytokines are mutually regulated molecules; thus the
balance between them influences CD4+ T-cell differentiation
towards Th1, Th2, or Th17 cells. IL-12 induces Th1-mediated
responses; meanwhile the anti-inflammatory cytokine IL-
10 suppresses the production of IL-12 among other Th1
cytokines. The observed differences in the production of IL-
12, IL-10, and TNF-𝛼 could contribute to understanding the
type of response a strain may promote [45, 46]. JCM 5818
showed the highest TNF-𝛼/IL-10 ratio whereas CIDCA 8348
presented the lower ratio. Moreover, CIDCA 8348 showed
also the highest IL-10/IL-12 ratio which presupposes that it
is a good anti-inflammatory candidate [47]. In concordance
with these results, the strain CIDCA 8348 was also capa-
ble, along with other two L. kefiri strains, of eliciting an
anti-inflammatory response on flagellin-stimulated intestinal
epithelial cells (Caco-ccl20 reporter system) which has been
previously reported for several probiotic bacteria [48] and
yeasts [18, 49]. Curiously, JCM 5818 strain that presented the
most anti-inflammatory capacity using Caco-ccl20 reporter
system presented the most proinflammatory profile using
PBMC. It might be interesting in the future to study the in
vivo anti-inflammatory properties of this strain.
Although in vitro research using PBMC from healthy
donors or intestinal epithelial cells can be used to screen the
immunomodulatory activity of probiotic strains candidates,
while reducing considerably the use of animals for screening
purposes, they could not always be a good indicator of in
vivo effect [4, 46, 47]. In consequence, to better understand
the immunomodulatory ability of L. kefiri, the strain CIDCA
8348 was selected to be administered orally to mice in order
to analyze the effect on different aspects of mucosal immune
response and microbiota modulation.
CIDCA 8348 strain occasioned an increment in IgA+
B cells in mLN and it correlated with an increase of IgA
in fecal samples of L. kefiri-treated mice. These findings are
in agreement with results reported for some lactobacilli-
based probiotics [50, 51] or even for the administration
of kefir-fermented milk [16, 52]. SIgA, the predominant
immunoglobulin in secretions, is a key element in maintain-
ing gut homeostasis and in the protection ofmucosal surfaces
against pathogens [53]. Expression of molecules involved in
class switch to IgA, expansion of IgA-expressing B cells, and
their differentiation to IgA secreting plasma cells was studied.
Even though no changes in the expression of APRIL, BAFF,
and TGF𝛽1 genes in PP, mLN, ileum, or colon were observed,
IL-10 was significantly induced in both ileum and mLN. It
has been described that this cytokine induces IgAproduction,
either through induction of TGF𝛽 within the target B cell
itself or through enhancement of the postswitch maturation
[54]. Nevertheless, a downregulation of the expression of
proinflammatory cytokines (IL-1𝛽 and IL-17A) was observed
in ileum tissue at 7th day of administration of L. kefiri.
This effect became more evident after 21 days of treatment,
when a significant decrease of several proinflammatorymedi-
ators was determined in Peyer’s patches (IL-6, GM-CSF, IL-
17A, and IFN-𝛾), mesenteric lymphoid nodes (IL-6, GM-
CSF, and IL-17A), and colon (GM-CSF, IFN-𝛾, and IL-1𝛽)
showing the anti-inflammatory ability of this L. kefiri strain
in vivo. This kind of results, which support the suppression
of proinflammatory immunity by probiotics, was reported
for different nonpathogenic and probiotic bacteria by other
authors in healthy [55] or disease models [47], but this is the
first report for L. kefiri isolated from kefir.Moreover, the anti-
inflammatory cytokine IL-10 was increased in ileum as well
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Figure 6: Evaluation of microbiota on fecal samples taken on the 21st day of trial from control and Lk groups. (a) Total bacteria DGGE
profiles of fivemice from control group (lanes C1 to C5) and five from Lk group (lanes L1 to L5). (b) Dendrogram for the total bacterial DGGE
profiles. Clustering analysis was performed using the UPGMA linkage. (c) qPCR quantification of total bacteria, Firmicutes, Bacteroidetes,
and Lactobacillus spp. Results are expressed as mean ± standard deviation. ∗𝑃 < 0.05.
as the chemokine CXCL-1. This interesting chemoattractant,
analogous in function to human IL-8, is an important
regulator of neutrophil recruitment from the lamina propria
to the epithelium and has been shown to be essential in
protection against DSS-induced colitis [56].
On the other hand, intestinal explants from L. kefiri-
treated mice showed a downregulation of IL-6 and GM-
CSF after in vitro stimulation with a proinflammatory medi-
ator such as LPS in comparison with control mice. Taken
together, all these experiments allowed us to confirm the anti-
inflammatory phenotype associated with L. kefiri CIDCA
8348 administration.
Regarding another feature on mucosal physiology, we
studied the effect of L. kefiri administration on the expression
of mucin genes. Mucins are the main component of the
mucus layer and it has been described that their secretion
could be modified by changes in host microbiota, infections,
and probiotic or antibiotic treatments [57–59]. Only a few
authors have evaluated the effect of probiotic administration
in healthy lab animals. Particularly, Dykstra et al. [60]
observed differential induction of muc1, muc2, and muc3
in ileum and colon after administration of Lactobacillus
plantarum 299 v to Sprague-Dawley rats. In addition, studies
performed in Swiss mice revealed that administration of
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L. plantarum L91 induced muc2 in colon [61]; meanwhile
Jiang et al. [62] reported that L. rhamnosus GG-treated
C57BL/6NHsd mice overexpressedmuc3 without changes in
muc1, muc2, or muc4. In L. kefiri-treated mice muc3 and
muc6 increased their expression in the ileum after 7 days of
treatment whereas at 21 days only muc6 was increased. In
colon, at 7 and 21 days muc4 expression was increased in L.
kefiri-treated mice. These changes could be associated with
the presence of L. kefiri in the gut or with the modifications
in microbiota populations induced by it [63]. Moreover,
differences in the quantity and composition of the local
microbiota [64] as well as the characteristics and thickness of
the mucus layer [58, 65] could have an impact in the way L.
kefiri interacts with the epithelium or its effect onmicrobiota.
5. Conclusion
In this study, we demonstrated that L. kefiri strains isolated
from kefir stimulated the production of different ratios of
pro/anti-inflammatory cytokines in vitro. We proved that the
administration of L. kefiri CIDCA 8348 to mice not only
downregulates expression of proinflammatory mediators but
also increases anti-inflammatory molecules in gut immune
system inductive and effector sites. Likewise, the increment
in IgA production together with mucin induction and the
impact in microbiota demonstrate the importance of this
probiotic in the regulation of intestinal homeostasis. Thus, it
is a good candidate to be used in gut inflammatory disorders.
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